Skip to main content
Clinical Trials/NL-OMON56404
NL-OMON56404
Recruiting
Not Applicable

Pancreatic Locally advanced Irresectable Cancer AblatioN (PELICAN trial) - PELICAN trial

Amsterdam UMC0 sites174 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Locally advanced pancreatic cancer
Sponsor
Amsterdam UMC
Enrollment
174
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • 1\. Histologically or cytologically confirmed adenocarcinoma of the pancreas 2\.
  • Locally irresectable tumor (see Appendix 1 of the protocol for criteria) 3\.
  • Primary tumor 4\. Stable disease or partial respons after 2 months of induction
  • chemotherapy (according to RECIST) 5\. Fit for chemotherapy as assessed by the
  • medical oncologist plus: • Absolute neutrophil count \>\= 1\.5 × 10^9/L • Platelet
  • count \>\= 100 × 10^9/L • Renal function: creatinine clearance \> 50 ml/min •
  • Transaminases \<\= 3 x ULN 6\. Fit for surgery assessed by the treating surgeon and
  • anesthesiologist 7\. RFA technical feasible (see Appendix 2 of the protocol for
  • criteria) 8\. Written informed consent 9\. Age \>\= 18 years

Exclusion Criteria

  • 1\. WHO performance status 3 or 4 2\. Distant metastases on abdominal or thoracic
  • CT scan\* 3\. Previous surgical, local ablative or radiotherapy for pancreatic
  • cancer or chemotherapy which is inconsistent with the prescribed induction
  • schedule according to protocol\*\* 4\. Stenosis of \> 50% of the hepatic artery AND
  • portal vein/ superior mesenteric vein 5\. Second primary malignancy, except
  • adequately treated non\-melanoma skin cancer, in situ carcinoma of the cervix
  • uteri or other malignancies treated at least 5 years previously without signs
  • of recurrence. 6\. Pregnancy \* Positive or suspicious regional lymph node
  • metastases are not a reason for exclusion \*\* Surgical exploration is not a
  • contra\-indication for inclusion kan zij

Outcomes

Primary Outcomes

Not specified

Similar Trials